Terrence L Geiger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1576509/publications.pdf

Version: 2024-02-01

88 papers	5,471 citations	94433 37 h-index	82547 72 g-index
89 all docs	89 docs citations	89 times ranked	7719 citing authors

#	Article	IF	Citations
1	Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. Journal of Biological Chemistry, 1987, 262, 785-94.	3.4	930
2	Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 2004, 18, 676-684.	7.2	674
3	Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature, 2019, 576, 471-476.	27.8	251
4	IL-10 modulates DSS-induced colitis through a macrophageâ€“ROSâ€“NO axis. Mucosal Immunology, 2014, 7, 869-878.	6.0	160
5	Regulation of ZAP-70 Activation and TCR Signaling by Two Related Proteins, Sts-1 and Sts-2. Immunity, 2004, 20, 37-46.	14.3	145
6	A Kinetic and Dynamic Analysis of Foxp3 Induced in T Cells by TGF-Î². Journal of Immunology, 2007, 178, 7667-7677.	0.8	144
7	PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia, 2018, 32, 1157-1167.	7.2	144
8	Chronic TLR Stimulation Controls NLRP3 Inflammasome Activation through IL-10 Mediated Regulation of NLRP3 Expression and Caspase-8 Activation. Scientific Reports, 2015, 5, 14488.	3.3	120
9	Acetaminophen and Diphenhydramine Premedication for Allergic and Febrile Nonhemolytic Transfusion Reactions: Good Prophylaxis or Bad Practice?. Transfusion Medicine Reviews, 2007, 21, 1-12.	2.0	113
10	Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut, 2020, 69, 1053-1063.	12.1	109
11	Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatric Blood and Cancer, 2005, 45, 10-15.	1.5	106
12	Mitigation of Experimental Allergic Encephalomyelitis by TGF-Î² Induced Foxp3+ Regulatory T Lymphocytes through the Induction of Anergy and Infectious Tolerance. Journal of Immunology, 2008, 180, 2830-2838.	0.8	106
13	Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood, 2005, 105, 2090-2092.	1.4	99
14	A large-scale method for the selective depletion of Î±Î² T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy, 2007, 9, 746-754.	0.7	99
15	IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11817-11822.	7.1	89
16	Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. British Journal of Haematology, 2005, 130, 781-787.	2.5	87
17	Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica, 2015, 100, 336-344.	3.5	84
18	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer, 2008, 113, 522-529.	4.1	83

#	Article	IF	Citations
19	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	7.4	83
20	Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood, 2001, 98, 2364-2371.	1.4	80
21	The neoepitope landscape in pediatric cancers. Genome Medicine, 2017, 9, 78.	8.2	77
22	Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein. International Immunology, 1995, 7, 715-725.	4.0	72
23	Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy, 2003, 5, 479-484.	0.7	71
24	A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy, 2004, 6, 1-6.	0.7	70
25	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8 ⁺ T cell responses. Science Translational Medicine, 2019, 11, .	12.4	66
26	Identification of errors introduced during high throughput sequencing of the T cell receptor repertoire. BMC Genomics, 2011, 12, 106.	2.8	65
27	IL-6 Promotes T Cell Proliferation and Expansion under Inflammatory Conditions in Association with Low-Level RORÎ³t Expression. Journal of Immunology, 2018, 201, 2934-2946.	0.8	65
28	Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells. Bone Marrow Transplantation, 2003, 31, 17-22.	2.4	61
29	T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2985-2989.	7.1	59
30	Nature and nurture in Foxp3+ regulatory T cell development, stability, and function. Human Immunology, 2012, 73, 232-239.	2.4	56
31	Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell, 2006, 10, 179-190.	16.8	54
32	IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis. Nature Communications, 2015, 6, 6131.	12.8	50
33	A Mouse Model of Clonal CD8+ T Lymphocyte-Mediated Alopecia Areata Progressing to Alopecia Universalis. Journal of Immunology, 2012, 188, 477-486.	0.8	49
34	Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytes. Nature Biotechnology, 2002, 20, 1215-1220.	17.5	48
35	A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplantation, 2002, 30, 69-74.	2.4	47
36	Uncoupling of IL-2 Signaling from Cell Cycle Progression in Naive CD4+ T Cells by Regulatory CD4+CD25+ T Lymphocytes. Journal of Immunology, 2005, 174, 155-163.	0.8	46

#	Article	IF	Citations
37	Clonal Deletion of Simian Virus 40 Large T Antigen-Specific T Cells in the Transgenic Adenocarcinoma of Mouse Prostate Mice: An Important Role for Clonal Deletion in Shaping the Repertoire of T Cells Specific for Antigens Overexpressed in Solid Tumors. Journal of Immunology, 2002, 169, 4761-4769.	0.8	40
38	T Cell Receptor CDR3 Sequence but Not Recognition Characteristics Distinguish Autoreactive Effector and Foxp3+ Regulatory T Cells. Immunity, 2009, 31, 909-920.	14.3	36
39	Preferential Use of Public TCR during Autoimmune Encephalomyelitis. Journal of Immunology, 2016, 196, 4905-4914.	0.8	35
40	A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. Journal of Immunology, 2007, 179, 11 p following 1390.	0.8	35
41	Etiology and Outcome of Graft Failure in Pediatric Hematopoietic Stem Cell Transplant Recipients. Journal of Pediatric Hematology/Oncology, 2003, 25, 955-959.	0.6	32
42	Retrogenic Modeling of Experimental Allergic Encephalomyelitis Associates T Cell Frequency but Not TCR Functional Affinity with Pathogenicity. Journal of Immunology, 2008, 181, 136-145.	0.8	32
43	Diversification and senescence of <scp>F</scp>oxp3⁺ regulatory <scp>T</scp> cells during experimental autoimmune encephalomyelitis. European Journal of Immunology, 2013, 43, 1195-1207.	2.9	29
44	Converting antigen-specific diabetogenic CD4 and CD8 T cells to TGF-beta producing non-pathogenic regulatory cells following FoxP3 transduction. Journal of Autoimmunity, 2007, 28, 188-200.	6.5	28
45	Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CARâ€“T-cell responses against ALL. Blood, 2021, 138, 122-135.	1.4	28
46	Antigen Nonspecific Suppression of T Cell Responses by Activated Stimulation-Refractory CD4+ T Cells. Journal of Immunology, 2004, 172, 2238-2246.	0.8	27
47	Modulation of PI3K signaling to improve CAR T cell function. Oncotarget, 2018, 9, 35807-35808.	1.8	27
48	Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood, 2003, 102, 4320-4325.	1.4	25
49	A revised classification scheme for acute transfusion reactions. Transfusion, 2007, 47, 621-628.	1.6	24
50	IL-10-Dependent Suppression of Experimental Allergic Encephalomyelitis by Th2-Differentiated, Anti-TCR Redirected T Lymphocytes. Journal of Immunology, 2005, 174, 3789-3797.	0.8	23
51	Subtle Affinity-Enhancing Mutations in a Myelin Oligodendrocyte Glycoprotein-Specific TCR Alter Specificity and Generate New Self-Reactivity. Journal of Immunology, 2009, 182, 4439-4447.	0.8	23
52	Rational Design of T Cell Receptors with Enhanced Sensitivity for Antigen. PLoS ONE, 2011, 6, e18027.	2.5	22
53	Gut Microbial Dysbiosis Due toHelicobacterDrives an Increase in Marginal Zone B Cells in the Absence of IL-10 Signaling in Macrophages. Journal of Immunology, 2015, 195, 3071-3085.	0.8	21
54	Defective cell cycle induction by IL-2 in naive T-cells antigen stimulated in the presence of refractory T-lymphocytes. International Immunology, 2006, 18, 1043-1054.	4.0	20

#	Article	IF	Citations
55	T cell metabolism in homeostasis and cancer immunity. Current Opinion in Biotechnology, 2021, 68, 240-250.	6.6	20
56	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Advances, 2022, 6, 5737-5749.	5.2	20
57	Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfusion Medicine Reviews, 2001, 15, 21-34.	2.0	19
58	Discrete TCR Repertoires and CDR3 Features Distinguish Effector and Foxp3+ Regulatory T Lymphocytes in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Allergic Encephalomyelitis. Journal of Immunology, 2010, 185, 3895-3904.	0.8	19
59	Differential T Cell Cytokine Receptivity and Not Signal Quality Distinguishes IL-6 and IL-10 Signaling during Th17 Differentiation. Journal of Immunology, 2016, 196, 2973-2985.	0.8	19
60	Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes. Gene Therapy, 2003, 10, 594-604.	4.5	18
61	The T Cell Response to IL-10 Alters Cellular Dynamics and Paradoxically Promotes Central Nervous System Autoimmunity. Journal of Immunology, 2012, 189, 669-678.	0.8	18
62	New approaches for the immunotherapy of acute myeloid leukemia. Discovery Medicine, 2015, 19, 275-84.	0.5	18
63	Prediction of CD34 + cell yield in hematopoietic cell products from children by peripheral blood CD34 + cell counts. Cytotherapy, 2012, 14, 473-482.	0.7	15
64	Context and location dependence of adaptive Foxp3+ regulatory T cell formation during immunopathological conditions. Cellular Immunology, 2012, 279, 60-65.	3.0	15
65	Bispecificity for Myelin and Neuronal Self-Antigens Is a Common Feature of CD4 T Cells in C57BL/6 Mice. Journal of Immunology, 2014, 193, 3267-3277.	0.8	14
66	Autoimmune susceptibility imposed by public TCRÎ² chains. Scientific Reports, 2016, 6, 37543.	3.3	14
67	A case of hemoglobin SC disease with cold agglutinin-induced hemolysis. American Journal of Hematology, 2005, 78, 37-40.	4.1	13
68	Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-Î¶ Chimeric Receptor. Journal of Immunology, 2008, 180, 3601-3611.	0.8	13
69	Rebalancing Immune Specificity and Function in Cancer by T-Cell Receptor Gene Therapy. Archivum Immunologiae Et Therapiae Experimentalis, 2010, 58, 335-346.	2.3	11
70	Transfusionâ€associated immune modulation: a reason to TRIM platelet transfusions?. Transfusion, 2008, 48, 1772-1773.	1.6	10
71	Functional Segregation of the TCR and Antigen-MHC Complexes on the Surface of CTL. Journal of Immunology, 2003, 171, 4089-4095.	0.8	8
72	The effect of solvent/detergent-treated plasma on red cells stored in vitro. Transfusion, 1995, 35, 487-492.	1.6	6

#	Article	IF	Citations
73	Human leucocyte antigen alloimmunization after bone marrow transplantation: an association with chronic myelogenous leukaemia. British Journal of Haematology, 2002, 117, 634-641.	2.5	4
74	Induction of B-Cell Immune Tolerance by Antigen-Modified Cytotoxic T Lymphocytes. Transplantation, 2010, 89, 667-676.	1.0	4
75	Turning Tregs into class I suppressors. Blood, 2012, 119, 3373-3374.	1.4	4
76	In Vivo Suppression of Naive CD4 T Cell Responses by IL-2- and Antigen-Stimulated T Lymphocytes in the Absence of APC Competition. Journal of Immunology, 2008, 181, 3323-3335.	0.8	3
77	Altered Differentiation, Diminished Pathogenicity, and Regulatory Activity of Myelin-Specific T Cells Expressing an Enhanced Affinity TCR. Journal of Immunology, 2011, 187, 5521-5531.	0.8	3
78	Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. Journal of Pediatric Hematology/Oncology, 2018, 40, e479-e485.	0.6	3
79	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. Blood, 2020, 136, 39-40.	1.4	3
80	Opposing Effects of PD-1/PD-L1/L2 Engagement and IFN-Î³/TNF-Î± in the Treatment of AML w/ Anti-CD33 Chimeric Antigen Receptor-Modified T Cells. Blood, 2016, 128, 5891-5891.	1.4	2
81	Contribution of donorâ€•and recipientâ€•associated factors to allergic transfusion reactions to platelets. Transfusion, 2021, 61, 744-753.	1.6	2
82	Monogamy and polygamy in T-cell receptor (TCR) chain association. Blood, 2007, 109, 5-6.	1.4	1
83	Induction of tolerance and immunity by redirected B cell-specific cytolytic T lymphocytes. Gene Therapy, 2007, 14, 1739-1749.	4.5	1
84	Hypocalcemic Tetany After Transfusion of a Small Amount of Blood Product. Journal of Pediatric Hematology/Oncology, 2017, 39, 629-632.	0.6	1
85	Anti-CD33 Chimeric Antigen Receptor Therapy For Acute Myeloid Leukemia. Blood, 2013, 122, 1441-1441.	1.4	1
86	Central Tolerance in a Prostate Cancer Model TRAMP Mouse. Annals of the New York Academy of Sciences, 2003, 987, 322-323.	3.8	0
87	Principles of the Immune System Central to Transfusion Medicine. , 2007, , 15-29.		0
88	Defective Cell Cycle Induction by IL-2 in Naiì¨ve T-Cells Antigen-Stimulated in the Presence of Refractory T-Lymphocytes.. Blood, 2005, 106, 3298-3298.	1.4	0